LAG3 - lymphocyte activating 3 Gene
Species: Canis lupus familiaris (sub-species: familiaris)
Gene Type: protein coding
Gene ID: 486720
LAG3 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| XM_038439159.1 | XP_038295087.1 | lymphocyte activation gene 3 protein |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
lymphocyte activation gene 3 protein |
|
Related Agents
- Clinical Phase
- Pre-clinical Phase
Clinical Phase
Inhibitory Antibodies
(15)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P99156 | Relatlimab | 98.00% | Phase 4 | |
| HY-P99573 | Tebotelimab | 99.52% | Phase 3 | |
| HY-P99613 | Favezelimab | 97.79% | Phase 3 | |
| HY-P99617 | Fianlimab | 99.04% | Phase 3 | |
| HY-P990968 | Alcestobart | 98.383% | Phase 3 | |
| HY-P99027 | Ieramilimab | ≥99.0% | Phase 2 | |
| HY-P990750 | Negalstobart | 96.89% | Phase 2 | |
| HY-P990700 | Tobemstomig | 97.06% | Phase 2 | |
| HY-P99736 | Miptenalimab | 97.04% | Phase 2 | |
| HY-P990046 | Tuparstobart | 97.65% | Phase 2 | |
| HY-P990740 | Fanastomig | 95.478% | Phase 2 | |
| HY-P991300 | GSK2831781 | Inhibitor | / | Phase 2 |
| HY-P991605 | HLX26 | Inhibitor | / | Phase 2 |
| HY-P991301 | IMP-761 | Inhibitor | 97.24% | Phase 1 |
| HY-P991303 | TQB-2223 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(21)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-108691 | PF-06465469 | Inhibitor | 99.48% | Unkown |
| HY-144088 | ZYF0033 | Inhibitor | 98.82% | Unkown |
| HY-172930 | PVTX-405 | / | Unkown | |
| HY-176813 | LAG-3 Hit II | Inhibitor | 99.58% | Unkown |
| HY-162811 | LAG-3 biner 1 | 97.08% | Unkown | |
| HY-164308 | SA-15-P | Inhibitor | 99.62% | Unkown |
| HY-122081 | CPI-644 | Inhibitor | / | Unkown |
| HY-145240 | eIF4E-IN-1 | Inhibitor | / | Unkown |
| HY-149916 | A2AR-antagonist-1 | Antagonist | 96.68% | Unkown |
| HY-176814 | LAG-3-IN-1 | Inhibitor | / | Unkown |
| HY-178320 | LAG-3-IN-2 | Inhibitor | / | Unkown |
| HY-179060 | LAG-3 PROTAC-1 | Degrader | / | Unkown |
| HY-179061 | LAG-3 degrader 1 | Degrader | / | Unkown |
| HY-179071 | DAPK1 ligand-1 | Degrader | / | Unkown |
| HY-180900 | Z3071585108 | Ligand | / | Unkown |
| HY-181685 | LAGi-DEL | Inhibitor | / | Unkown |
| HY-P10835 | LAG-3 cyclic peptide inhibitor C25 | Inhibitor | / | Unkown |
| HY-P10837 | LAG-3 cyclic peptide inhibitor 12 | Inhibitor | / | Unkown |
| HY-RS07492 | LAG3 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS16686 | Lag3 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23121 | Lag3 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(15)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99141 | Anti-Mouse LAG-3 Antibody (C9B7W) | Inhibitor | 99% | Unkown |
| HY-P99922 | Encelimab | Inhibitor | 95.25% | Unkown |
| HY-P990976 | Brivestobart | 99.198% | Unkown | |
| HY-P990912 | Cugrastomig | 98.46% | Unkown | |
| HY-P99354 | Bavunalimab | 99.408% | Unkown | |
| HY-P991297 | AM0003 | Inhibitor | / | Unkown |
| HY-P991298 | DNV-3 | Inhibitor | / | Unkown |
| HY-P991299 | ENUM006 | Inhibitor | / | Unkown |
| HY-P991302 | KL-A289 | Inhibitor | / | Unkown |
| HY-P992075 | Anti-Bovine LAG-3 Antibody (2D8) | Inhibitor | / | Unkown |
| HY-P992254 | Anti-LAG-3 Antibody (BAP050) | Inhibitor | / | Unkown |
| HY-P992352 | ES005 | / | Unkown | |
| HY-P992461 | SHR-1802 | Inhibitor | / | Unkown |
| HY-P990204 | Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) | Inhibitor | / | Unkown |
| HY-P992156 | Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service